These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 16984213)

  • 1. Pharmacokinetic profile of the somatostatin analogue lanreotide in individuals with chronic hepatic insufficiency.
    Tomlinson B; Thomas NG; Lan IW; Barbanoj M; Antonijoan RM; Drazna E; Ramis J; Obach R; Peraire C
    Clin Pharmacokinet; 2006; 45(10):1003-11. PubMed ID: 16984213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of a new Autogel formulation of the somatostatin analogue lanreotide after a single subcutaneous dose in healthy volunteers.
    Antonijoan RM; Barbanoj MJ; Cordero JA; Peraire C; Obach R; Vallès J; Chérif-Cheikh R; Torres ML; Bismuth F; Montes M
    J Pharm Pharmacol; 2004 Apr; 56(4):471-6. PubMed ID: 15099442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of the somatostatin analog lanreotide in patients with severe chronic renal insufficiency.
    Barbanoj M; Antonijoan R; Morte A; Grinyó JM; Solà R; Vallès J; Peraire C; Cordero JA; Muñoz A; Jané F; Obach R
    Clin Pharmacol Ther; 1999 Nov; 66(5):485-91. PubMed ID: 10579475
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetic analysis of lanreotide Autogel in healthy subjects : evidence for injection interval of up to 2 months.
    Trocóniz IF; Cendrós JM; Peraire C; Ramis J; Garrido MJ; Boscani PF; Obach R
    Clin Pharmacokinet; 2009; 48(1):51-62. PubMed ID: 19071884
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population Pharmacokinetic Analysis of Lanreotide Autogel/Depot in the Treatment of Neuroendocrine Tumors: Pooled Analysis of Four Clinical Trials.
    Buil-Bruna N; Garrido MJ; Dehez M; Manon A; Nguyen TX; Gomez-Panzani EL; Trocóniz IF
    Clin Pharmacokinet; 2016 Apr; 55(4):461-73. PubMed ID: 26416534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lanreotide effect on splanchnic blood flow in healthy subjects: effect of the rate of infusion.
    Sieber CC; Beglinger C; Bart S; Tschoepl M; Currie G; Larsen F; Drewe J
    Clin Pharmacol Ther; 2004 Jan; 75(1):70-9. PubMed ID: 14749693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic profile of lanreotide Autogel in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days.
    Bronstein M; Musolino N; Jallad R; Cendros JM; Ramis J; Obach R; Leselbaum A; Catus F
    Clin Endocrinol (Oxf); 2005 Nov; 63(5):514-9. PubMed ID: 16268802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alfentanil-induced miosis as a surrogate measure of alfentanil pharmacokinetics in patients with mild and moderate liver cirrhosis.
    Baririan N; Van Obbergh L; Desager JP; Verbeeck RK; Wallemacq P; Starkel P; Horsmans Y
    Clin Pharmacokinet; 2007; 46(3):261-70. PubMed ID: 17328584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single- and multiple-dose administration of caspofungin in patients with hepatic insufficiency: implications for safety and dosing recommendations.
    Mistry GC; Migoya E; Deutsch PJ; Winchell G; Hesney M; Li S; Bi S; Dilzer S; Lasseter KC; Stone JA
    J Clin Pharmacol; 2007 Aug; 47(8):951-61. PubMed ID: 17660480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel.
    Caron P; Bex M; Cullen DR; Feldt-Rasmussen U; Pico Alfonso AM; Pynka S; Racz K; Schopohl J; Tabarin A; Valimaki MJ;
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):734-40. PubMed ID: 15163338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and safety of galantamine in subjects with hepatic impairment and healthy volunteers.
    Zhao Q; Iyer GR; Verhaeghe T; Truyen L
    J Clin Pharmacol; 2002 Apr; 42(4):428-36. PubMed ID: 11936568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairment.
    Dowell JA; Stogniew M; Krause D; Damle B
    J Clin Pharmacol; 2007 Apr; 47(4):461-70. PubMed ID: 17389555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological and safety profile of a prolonged-release lanreotide formulation in acromegaly.
    Neggers S; Badiu C; Biagetti B; Durand-Gasselin L; Petit A; Petrossians P; Regnault B; Rich D; Shafigullina Z; Shustov S; Vydrych A
    Expert Rev Clin Pharmacol; 2021 Dec; 14(12):1551-1560. PubMed ID: 34664531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic and pharmacodynamic properties of a long-acting formulation of the new somatostatin analogue, lanreotide, in normal healthy volunteers.
    Kuhn JM; Legrand A; Ruiz JM; Obach R; De Ronzan J; Thomas F
    Br J Clin Pharmacol; 1994 Sep; 38(3):213-9. PubMed ID: 7826822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and population pharmacodynamic analysis of lanreotide Autogel.
    Cendros JM; Peraire C; Trocóniz IF; Obach R
    Metabolism; 2005 Oct; 54(10):1276-81. PubMed ID: 16154424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of hepatic impairment on the pharmacokinetics of pasireotide (SOM230): results from a multicenter phase I study.
    Horsmans Y; Hu K; Ruffin M; Wang Y; Song D; Bouillaud E; Wang Y; Mazur D; Botha FP; Heuman DM
    J Clin Pharmacol; 2012 Apr; 52(4):552-8. PubMed ID: 22282526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study.
    Yin OQ; Gallagher N; Tanaka C; Fisher D; Sethuraman V; Zhou W; Lin TH; Heuman D; Schran H
    Clin Ther; 2009; 31 Pt 2():2459-69. PubMed ID: 20110053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic properties of combination oxycodone plus racemic ibuprofen: two randomized, open-label, crossover studies in healthy adult volunteers.
    Kapil R; Nolting A; Roy P; Fiske W; Benedek I; Abramowitz W
    Clin Ther; 2004 Dec; 26(12):2015-25. PubMed ID: 15823765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tolerability and dose proportional pharmacokinetics of pasireotide administered as a single dose or two divided doses in healthy male volunteers: a single-center, open-label, ascending-dose study.
    Petersenn S; Hu K; Maldonado M; Zhang Y; Lasher J; Bouillaud E; Wang Y; Mann K; Unger N
    Clin Ther; 2012 Mar; 34(3):677-88. PubMed ID: 22364824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.